The antitumor effects of low-energy laser irradiation (LELI) are always the focus of scientific investigation. The purpose of this study was to test the effects of low-energy He-Ne laser irradiation on mouse S180 ascites sarcoma. After innoculating S180 sarcoma cells at the dosage of 1 x 106 cells per mouse, five group of BALB/c mice were irradiated at the spot of one Harder's glands of the mouse eye for six days with five different dosages of 7.33, 11.00, 14.67, 22.00 and 29.33 J/cm2 respectively. The antitumor effects were evaluated in two aspects: life prolongation ratio and ascites growth of tumor-bearing mice. The results showed that low energy He-Ne laser irradiation of 7.33, 11.00, 14.67, 22.00 and 29.33 J/cm2 could inhibit the proliferation speed of S180 ascites sarcoma in vivo, and therefore could prolong the survival time of the tumor bearing mice in some degree. Moreover, the dosage of 14.67 J/cm2 showed the most remarkable inhibiting effects among the four dosages, and the life prolongation ratio was up to 45.51%. On the contrary, the proliferation speed of S180 ascites sarcoma cells in vivo was accelerated by the large dosage of 29.33 J/cm2 LELI and the survival time of the tumor bearing mice were remarkably shortened. Low energy He-Ne laser irradiation with proper dosages can inhibit the development of the mouse S180 ascites sarcoma, while too large dosage shows promotive effects.
By using the experimental model of mouse S180 ascites sarcoma, the feasibility and mechanism of low-energy laser therapy combined with the traditional antitumor drug of cyclophosphamide in the treatment of malignant tumors were discussed. The S180 ascites sarcoma suffering BALB/c mice were irradiated upon the Harder's glands with the dosages of 11.00, 14.67 and 22.00 J/cm2 respectively, and/or injected with CYT intraperitoneally to evaluate the therapeutic effects of CYT/LELT combination on malignant tumors. The three dosages of LELT combined with CYT all showed remarkably therapeutic effects on the mouse S180 ascites sarcoma. Comparatively, the dosage of 14.67J/cm2 LELT combined with CYT showed the most ideal therapeutic effects and the survival time was up to 20.80 days, and the life prolongation ratio was 33.33% which was remarkably higher than those of the CYT and tumor control groups. CYT/LELT combined therapy had remarkably inhibiting effects on the mice ascites growth because of the existence of CYT.